Arcellx Stock Performance
| ACLX Stock | USD 64.69 1.16 1.76% |
The firm shows a Beta (market volatility) of 1.19, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Arcellx will likely underperform. Arcellx right now shows a risk of 3.83%. Please confirm Arcellx potential upside, and the relationship between the jensen alpha and rate of daily change , to decide if Arcellx will be following its price patterns.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Arcellx has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly strong essential indicators, Arcellx is not utilizing all of its potentials. The latest stock price disturbance, may contribute to short-term losses for the investors. ...more
1 | Disposition of 1500 shares by Patel Kavita of Arcellx at 57.5 subject to Rule 16b-3 | 04/08/2025 |
2 | Disposition of 1500 shares by Patel Kavita of Arcellx at 64.2 subject to Rule 16b-3 | 04/29/2025 |
3 | Arcellx Maintains Rating as Price Target is Lowered by Scotiabank ACLX Stock News | 05/09/2025 |
4 | Arcellx, Inc. Shares Sold by Wexford Capital LP | 05/19/2025 |
5 | Arcellx, Inc. Director Kavita Patel Sells 1,500 Shares of Stock | 05/21/2025 |
6 | Disposition of 8449 shares by Michelle Gilson of Arcellx at 64.3755 subject to Rule 16b-3 | 05/27/2025 |
7 | Acquisition by Lubner David Charles of 9174 shares of Arcellx at 63.68 subject to Rule 16b-3 | 05/29/2025 |
8 | Acquisition by Rami Elghandour of 223964 shares of Arcellx subject to Rule 16b-3 | 06/09/2025 |
9 | arcellx director Kavita Patel sells shares worth 101,040 - Investing.com | 06/11/2025 |
10 | Arcellx versus Novavax Head to Head Analysis | 06/16/2025 |
11 | Arcellx Citi Initiates Buy Rating with Promising Outlook ACLX Stock News | 06/17/2025 |
12 | FDA Eases Access To Life-Saving Gene Therapies For Blood Cancers | 06/30/2025 |
| Begin Period Cash Flow | 398.9 M |
Arcellx Relative Risk vs. Return Landscape
If you would invest 6,723 in Arcellx on April 2, 2025 and sell it today you would lose (254.00) from holding Arcellx or give up 3.78% of portfolio value over 90 days. Arcellx is currently generating 0.0131% in daily expected returns and assumes 3.8256% risk (volatility on return distribution) over the 90 days horizon. In different words, 34% of stocks are less volatile than Arcellx, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Arcellx Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Arcellx's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Arcellx, and traders can use it to determine the average amount a Arcellx's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0034
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | ACLX |
Estimated Market Risk
| 3.83 actual daily | 34 66% of assets are more volatile |
Expected Return
| 0.01 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| 0.0 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Arcellx is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Arcellx by adding Arcellx to a well-diversified portfolio.
Arcellx Fundamentals Growth
Arcellx Stock prices reflect investors' perceptions of the future prospects and financial health of Arcellx, and Arcellx fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Arcellx Stock performance.
| Return On Equity | -0.36 | ||||
| Return On Asset | -0.17 | ||||
| Profit Margin | (2.11) % | ||||
| Operating Margin | (8.48) % | ||||
| Current Valuation | 3.14 B | ||||
| Shares Outstanding | 55.11 M | ||||
| Price To Book | 8.70 X | ||||
| Price To Sales | 47.24 X | ||||
| Revenue | 107.94 M | ||||
| Gross Profit | (98.77 M) | ||||
| EBITDA | (99.06 M) | ||||
| Net Income | (107.35 M) | ||||
| Cash And Equivalents | 306.99 M | ||||
| Cash Per Share | 7.01 X | ||||
| Total Debt | 54.08 M | ||||
| Debt To Equity | 0.09 % | ||||
| Book Value Per Share | 7.57 X | ||||
| Cash Flow From Operations | (83.47 M) | ||||
| Earnings Per Share | (2.99) X | ||||
| Total Asset | 711.33 M | ||||
| Retained Earnings | (496.83 M) | ||||
About Arcellx Performance
Evaluating Arcellx's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Arcellx has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Arcellx has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. Arcellx, Inc. was incorporated in 2014 and is headquartered in Gaithersburg, Maryland. Arcellx operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 78 people.Things to note about Arcellx performance evaluation
Checking the ongoing alerts about Arcellx for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Arcellx help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Arcellx had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 107.94 M. Net Loss for the year was (107.35 M) with loss before overhead, payroll, taxes, and interest of (98.77 M). | |
| Arcellx currently holds about 306.99 M in cash with (83.47 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.01. | |
| Arcellx has a frail financial position based on the latest SEC disclosures | |
| Over 86.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from benzinga.com: FDA Eases Access To Life-Saving Gene Therapies For Blood Cancers |
- Analyzing Arcellx's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Arcellx's stock is overvalued or undervalued compared to its peers.
- Examining Arcellx's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Arcellx's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Arcellx's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Arcellx's stock. These opinions can provide insight into Arcellx's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Arcellx Stock Analysis
When running Arcellx's price analysis, check to measure Arcellx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arcellx is operating at the current time. Most of Arcellx's value examination focuses on studying past and present price action to predict the probability of Arcellx's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arcellx's price. Additionally, you may evaluate how the addition of Arcellx to your portfolios can decrease your overall portfolio volatility.